

**NOTICE**

**Regarding the Correction of previously disclosed information**

To: - State Securities Commission  
- Hanoi Stock Exchange

Agimexpharm Pharmaceutical Joint Stock Company hereby corrects the information previously disclosed pursuant to the Resolution of the Board of Directors No. 02/NQ-AGP.HDQT and the Report No. 01/BC-AGP dated January 9, 2026 regarding the results of the public offering of shares, as follows:

Document	Information content	Previously disclosed	Corrected
Resolution No. 02/NQ-AGP.HDQT dated January 9, 2026	Clause 10, Article 1	Expected share transfer date: - For existing shareholders exercising their rights to purchase shares from December 4, 2025 to December 25, 2025, and investors allocated odd shares arising from rounding down: Q1/2026. - For investors allocated the remaining shares not fully subscribed due to existing shareholders' failure to register for or pay for the purchase: Q1/2027	Expected share transfer date: Q1/2026.
Report No. 01/BC-AGP dated January 9, 2026	Clause 9, Section II	Expected share transfer date: - For existing shareholders exercising their rights to purchase shares from December 4, 2025 to December 25, 2025, and investors allocated odd shares arising from rounding down: Q1/2026. - For investors allocated the remaining shares not fully subscribed due to existing shareholders' failure to register for or pay for the purchase: Q1/2027	Expected share transfer date: Q1/2026.

**Recipients:**

- As stated above;
- Board of Directors, Board of Supervisors, Board of Management;
- Archived: Board of Directors' Secretariat.

ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRPERSON



PHARM. PHAM THI BICH THUY



## **RESOLUTION**

### **On approval of the results of the public offering of additional shares to existing shareholders**

Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and its amendments and supplements;

Pursuant to the Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its amendments and supplements;

Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 of the Government detailing and guiding the implementation of a number of articles of the Law on Securities, as amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;

Pursuant to the Charter on organization and operation of Agimexpharm Pharmaceutical JSC;

Pursuant to the Resolution of the General Meeting of Shareholders No. 02/NQ-AGP.DHDCD dated August 25, 2025 of Agimexpharm Pharmaceutical Joint Stock Company adopted by written voting and Proposal No. 07/TT-AGP.DHDCD dated August 12, 2025 on approval of the plan for public offering of additional shares to existing shareholders;

Pursuant to the Certificate of Registration for public offering of additional shares issued by the State Securities Commission No. 419/GCN-UBCK dated November 12, 2025;

Pursuant to the Resolution of the Board of Directors No. 16/NQ-AGP.HDQT dated December 31, 2026 on approval of results of the exercise of subscription rights and plan for handling fractional shares and unsubscribed shares arising from the public offering of additional shares to existing shareholders;

Pursuant to the actual results of the offering;

Pursuant to the confirmation issued by the bank where the escrow account is opened regarding the proceeds collected from the offering;

Pursuant to the Minutes of the Meeting of the Board of Directors of Agimexpharm Pharmaceutical Joint Stock Company No. 01/BB-AGP.HDQT dated January 09, 2026.

### **HEREBY RESOLVES:**

**Article 1:** To approve the results of the public offering of additional shares to existing shareholders of Agimexpharm Pharmaceutical Joint Stock Company (the "Company") in accordance with the Certificate of Registration for the public offering of additional shares No. 419/GCN-UBCK issued by the Chairman of the State Securities Commission of Vietnam on November 12, 2025, as follows:

#### **Summary of the results of the public offering of additional shares to existing shareholders**

1. Name of shares: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Type of shares: Ordinary shares
3. Stock code: AGP
4. Offering price: VND 25,000/share
5. Number of shares registered for offering: 3,992,290 shares
6. Number of shares offered: 3,992,290 shares, equivalent to 100% of the total number of shares registered for offering, including:
  - Number of shares subscribed for and paid by shareholders/investors in the offering to existing shareholders up to December 25, 2025: 3,930,712 shares
  - Number of fractional shares arising from rounding down that were subscribed for and paid by other investors up to January 06, 2026: 344 shares



- Number of unsubscribed shares due to existing shareholders' failure to register or pay for the subscription that were subscribed for and paid by other investors up to January 06, 2026: 61,234 shares.
- 7. Total proceeds: VND 99,807,250,000
- 8. Number of shares after the offering: 30,607,558 shares
- 9. Closing date of the offering: January 06, 2026
- 10. Expected share transfer date: Q1/2026.
- 11. The balance of funds in the Company's escrow account, based on the Confirmation Letter issued by Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch regarding the confirmation of the escrow account balance for the offering (as of January 8, 2026), is VND 99,943,840,567.

The difference of VND 136,590,567 compared to the proceeds collected from the offering is attributable to the following reasons:

No.	Details of reasons	Amount (VND)
(1)	Balance prior to December 4, 2025 – the commencement date for share subscription registration and payment	(**) 136,50,488
	– Balance as of November 24, 2025	136,500,000
	– Interest accrued in the account (from November 24, 2025 to November 30, 2025)	4,488
(2)	Interest accrued in the account (up to December 31, 2025)	1,186,079
(3)	Transfer fee from the account of the Vietnam Securities Depository and Clearing Corporation (VSDC) to the Company's escrow account for receipt of share subscription proceeds	1,100,000
<b>Total = (1) + (2) – (3)</b>		<b>136,590,567</b>

(\*\*) Note: As of November 24, 2025, there was one (01) shareholder who registered to exercise the subscription right and paid the share purchase amount ahead of the deadline specified in the Public Offering Announcement No. 06/TB-AGP dated November 13, 2025 of Agimexpharm Pharmaceutical Joint Stock Company, with a payment amount of VND 136,500,000. The interest accrued on this amount up to November 30, 2025 was VND 4,488.

Summary of expenses for the additional public offering of shares to existing shareholders of the Company: **VND 479,800,000**, including:

- Underwriting fee (if any): VND 0.
- Share distribution fee (if any): VND 0.
- Issuance advisory/consulting fee (inclusive of 10% VAT): VND 385,000,000.
- Fee for issuance of the certificate of public offering of shares: VND 5,000,000.
- Fee charged by the Vietnam Securities Depository and Clearing Corporation (VSDC) for fixing the list of shareholders entitled to exercise subscription rights (inclusive of 10% VAT): VND 7,700,000.
- Audit fee for expected charter capital (inclusive of 8% VAT): VND 64,800,000.
- Transfer fee from the VSDC account to the Company's escrow account for receipt of share subscription proceeds (inclusive of 10% VAT): VND 1,100,000.
- Newspaper publication costs for disclosure of information related to the offering (inclusive of 8% VAT): VND 16,200,000.
- Other expenses: VND 0.

Net proceeds from the offering: **VND 99,327,450,000**.

**Article 2:** To authorize the General Director to direct and execute the signing of all documents, dossiers and relevant materials in accordance with applicable laws.

**Article 3:** Members of the Board of Directors, the Board of General Directors and relevant individuals of Agimexpharm Pharmaceutical Joint Stock Company shall be responsible for the implementation of this Resolution.

**Article 4:** This Resolution shall take effect from the date of signing./.

***Recipients:***

- As stated in Articles 2 and 3;
- Board of Directors, Board of Supervisors;
- Archived: BOD Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRPERSON**



**PHARM. PHAM THI BICH THUY**





## **REPORT**

### **Results of the public share offering**

*(Pursuant to the Certificate of Registration for the public offering of additional shares No. 419/GCN-UBCK dated November 12, 2025 issued by the Chairman of the State Securities Commission of Viet Nam)*

#### **To: State Securities Commission**

#### **I. INFORMATION ON THE ISSUING ORGANIZATION**

1. Full name of the issuer: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
2. Abbreviated name: AGIMEXPHARM
3. Head office address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Viet Nam
4. Telephone: 0296.3856961–3856964                      Fax: 0296.3857301  
Website: www.agimexpharm.com
5. Charter capital: VND 266,152,680,000
6. Stock code: AGP
7. Bank for payment account: Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch  
Account No.: 110000016076
8. Enterprise Registration Certificate No.: 1600699279, initially issued on June 3, 2004 by the An Giang Department of Planning and Investment; amended for the 20th time on August 1, 2025 by the An Giang Department of Finance
9. License for establishment and operation (if required by specialized laws): Certificate of Eligibility for Pharmaceutical Business No. 4526/DKKDD-AG; 3rd issuance: Certificate No. 4133/DKKDD-AG issued by the An Giang Department of Health on December 20, 2023 pursuant to Decision No. 662/QĐ-SYT dated July 25, 2024

#### **II. OFFERING PLAN**

1. Name of shares: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Type of shares: Ordinary shares
3. Number of shares offered: 3,992,290 shares, of which:
  - Shares offered by the issuer: 3,992,290 shares;
  - Shares offered by shareholders/owners/members: 0 share.
4. Offering price: VND 25,000/share.
5. Expected total proceeds: VND 99,807,250,000, of which:
  - Proceeds of the issuer: VND 99,807,250,000;
  - Proceeds of shareholders/owners/members: VND 0.



6. Distribution method: Offering to existing shareholders through the exercise of subscription rights at the ratio of 20:03 (*On the record date, each shareholder holding 01 share is entitled to 01 subscription right; every 20 rights entitle the holder to purchase 03 new shares*).
7. Subscription and payment period:
  - Transfer of subscription rights: From December 4, 2025 to December 18, 2025
  - Subscription and payment:
    - Existing shareholders exercising subscription rights: From December 4, 2025 to December 25, 2025
    - Investors purchasing unsubscribed shares: From January 05, 2026 to January 06, 2026
8. Closing date of the offering: January 06, 2026.
9. Expected share transfer date: Q1/2026.

### III. RESULTS OF THE SHARE OFFERING

Investor category	Offering price (VND/share)	Number of shares offered (ii)	Number of shares subscribed (iii)	Number of shares allocated (iii)	Number of subscribing investors	Number of allocated investors	Number of non-allocated investors	Remaining shares	Allocation ratio (iv)
1	2	3	4	5	6	7	8=6-7	9=3-5	10
1. Public share offering	25,000	3,992,290	3,930,712	3,930,712	604	604	0	61,578 (*)	98.46%
2. Handling of unsubscribed shares (i)	25,000	61,578	61,578	61,578	15	15	0	0	1.54%
<b>Total</b>		<b>3,992,290</b>	<b>3,992,290</b>	<b>3,992,290</b>	<b>605 (**)</b>	<b>605 (**)</b>	<b>0</b>	<b>0</b>	<b>100%</b>
1. Domestic investors	25,000	3,991,396	3,991,396	3,991,396	603	603	0	0	99.98%
2. Foreign investors and economic organizations with foreign ownership exceeding 50% of charter capital	25,000	894	894	894	02	02	0	0	0.02%
<b>Total</b>		<b>3,992,290</b>	<b>3,992,290</b>	<b>3,992,290</b>	<b>605</b>	<b>605</b>	<b>0</b>	<b>0</b>	<b>100%</b>

**Notes:**

(\*) The number of shares remaining unsubscribed in the offering is 61,578 shares (including 344 odd shares arising from rounding down and 61,234 shares not subscribed due to existing



shareholders' failure to register for or pay for the purchase). These shares were subsequently allocated by the Board of Directors to investors in accordance with Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025.

(\*\*) Among the 15 investors allocated the odd shares arising from rounding down and the unsubscribed shares due to existing shareholders' failure to register for or pay for the purchase in the additional public offering of shares to existing shareholders, 14 investors are existing shareholders of the Company. Accordingly, the total number of shareholders allocated shares is 605.

- (i) Unsubscribed shares of existing shareholders: subsequently allocated by the Board of Directors in accordance with Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the exercise of subscription rights and the plan for handling unsubscribed shares in the additional public offering of shares to existing shareholders. Accordingly, 15 investors were allocated a total of 61,578 shares. Detailed information on these investors is provided in the Appendix attached to this Report.
  - (ii) The number of shares offered based on subscription rights to domestic investors, foreign investors, and economic organizations with foreign investors holding more than 50% of charter capital is calculated on a rounding-down basis.
  - (iii) The number of shares registered for purchase and the number of shares allocated to domestic investors, foreign investors, and economic organizations with foreign investors holding more than 50% of charter capital include the number of shares subscribed through the exercise of subscription rights (including the exercise of rights after receiving transferred subscription rights) and the number of shares subsequently allocated pursuant to Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the exercise of subscription rights and the plan for handling unsubscribed shares in the additional public offering of shares to existing shareholders. All 15 investors allocated shares under this Resolution are domestic investors.
  - (iv) The allocation ratio is calculated by dividing the number of shares allocated (Column 5) of each group by the total number of shares offered (3,992,290 shares).
- In case of underwriting: disclosure of the allocation results to the underwriting organization(s) in accordance with the commitments under the underwriting agreement (quantity, price; where there is a syndicate, disclosure for each organization): Not applicable
  - In case the remaining shares are allocated to one or several identified investors: information on the number of shares and the offering ratio for each investor and their related persons in the charter capital in this offering and in offerings/issuances within the most recent 12 months; information on the ownership ratio of each investor and their related persons after the offering is detailed in Appendices I and II attached to this Report.

#### IV. SUMMARY OF THE OFFERING RESULTS

1. Total shares allocated: **3,992,290 shares**, equivalent to 100% of the offered shares, of which:
  - Shares of the issuer: 3,992,290 shares;
  - Shares of shareholders/owners/members: 0 share.
2. Total proceeds: **VND 99,807,250,000**, of which:
  - Proceeds of the issuer: VND 99,807,250,000;
  - Proceeds of shareholders/owners/members: VND 0.



**Notes:**

*The balance of funds in the Company's escrow account, based on the Confirmation Letter issued by Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch regarding the confirmation of the escrow account balance for the offering (as of January 8, 2026), is VND 99,943,840,567.*

*The difference of VND 136,590,567 compared to the proceeds collected from the offering is attributable to the following reasons:*

No.	Details of reasons	Amount (VND)
(1)	Balance prior to December 4, 2025 – the commencement date for share subscription registration and payment	(**) 136,50,488
	– Balance as of November 24, 2025	136,500,000
	– Interest accrued in the account (from November 24, 2025 to November 30, 2025)	4,488
(2)	Interest accrued in the account (up to December 31, 2025)	1,186,079
(3)	Transfer fee from the account of the Vietnam Securities Depository and Clearing Corporation (VSDC) to the Company's escrow account for receipt of share subscription proceeds	1,100,000
<b>Total = (1) + (2) – (3)</b>		<b>136,590,567</b>

*(\*\*) Notes: As of November 24, 2025, there was one (01) shareholder who registered to exercise the subscription right and paid the share purchase amount ahead of the deadline specified in the Public Offering Announcement No. 06/TB-AGP dated November 13, 2025 of Agimexpharm Pharmaceutical Joint Stock Company, with a payment amount of VND 136,500,000. The interest accrued on this amount up to November 30, 2025 was VND 4,488.*

**3. Total expenses: VND 479,800,000, including:**

- Underwriting fee (if any): VND 0.
- Share distribution fee (if any): VND 0.
- Issuance advisory/consulting fee (inclusive of 10% VAT): VND 385,000,000.
- Fee for issuance of the certificate of public offering of shares: VND 5,000,000.
- Fee charged by the Vietnam Securities Depository and Clearing Corporation (VSDC) for fixing the list of shareholders entitled to exercise subscription rights (inclusive of 10% VAT): VND 7,700,000.
- Audit fee for expected charter capital (inclusive of 8% VAT): VND 64,800,000.
- Transfer fee from the VSDC account to the Company's escrow account for receipt of share subscription proceeds (inclusive of 10% VAT): VND 1,100,000.
- Newspaper publication costs for disclosure of information related to the offering (inclusive of 8% VAT): VND 16,200,000.
- Other expenses: VND 0.

**4. Net proceeds from the offering: VND 99,327,450,000.**



## V. Capital structure of the issuer after the offering

### 1. Capital structure

No.	Category	Number of shareholders	Number of shares held (shares)	Par value of shares held (VND)	Ownership ratio (****) (%)
<b>I</b>	<b>Domestic and foreign shareholders</b>				
<b>1</b>	<b>Domestic</b>	<b>905</b>	<b>30,600,561</b>	<b>306,005,610,000</b>	<b>99.98%</b>
1.1	State	00	-	-	0.00%
1.2	Organizations	06	11,728,286	117,282,860,000	38.32%
1.3	Individuals	899	18,872,275	188,722,750,000	61.66%
<b>2</b>	<b>Foreign</b>	<b>03</b>	<b>6,997</b>	<b>69,970,000</b>	<b>0.02%</b>
2,1	Foreign organizations; economic organizations with foreign investors holding more than 50% of charter capital	00	-	-	0.00%
2,2	Individuals	03	6,997	69,970,000	0.02%
	<b>Total (1 + 2)</b>	<b>908</b>	<b>30,607,558</b>	<b>306,075,580,000</b>	<b>100.00%</b>
<b>II</b>	<b>Founding shareholders, major shareholders and other shareholders</b>				
1	Founding shareholders	00	0	0	0%
2	Major shareholders	04	19,364,328	193,643,280,000	63.27%
3	Shareholders holding less than 5% of voting shares	904	11,243,230	112,432,300,000	36.73%
	<b>Total (1 + 2 + 3)</b>	<b>908</b>	<b>30,607,558</b>	<b>306,075,580,000</b>	<b>100.00%</b>

(\*\*\*\*) Note: The ownership ratio is calculated based on the number of voting shares (30,607,558 shares).

### 2. List and ownership ratio of major shareholders

No.	Shareholder's name	Citizen ID No./ Enterprise Registration Certificate and date of issuance	Number of shares held (shares)	Ownership ratio (*****)
1	Imexpfarm Pharmaceutical Joint Stock Company	1400384433, initially issued by Dong Thap Department of Planning and Investment on August 1, 2001; amended for the 33rd time by Dong Thap Department of Finance on October 8, 2024	9,239,832	30.19%
2	Lien Phat Vung Tau Joint Stock Company	0318503862, initially issued by Ho Chi Minh City Department of Planning and	2,202,753	7.20%



No.	Shareholder's name	Citizen ID No./ Enterprise Registration Certificate and date of issuance	Number of shares held (shares)	Ownership ratio (*****)
		Investment on June 11, 2024; amended for the 1st time by Ho Chi Minh City Department of Finance on June 2, 2025		
3	Pham Uyen Nguyen	079068011560, issued on June 18, 2024	4,387,766	14.34%
4	Nguyen Van Kha	089053000074, issued on July 26, 2024	3,533,977	11.55%
	<b>Total</b>		<b>19,364,328</b>	<b>63.27%</b>

Source: Based on the list of shareholders entitled to purchase shares from the additional public offering of shares to existing shareholders finalized by the Vietnam Securities Depository and Clearing Corporation (VSDC) as of November 27, 2025, and the consolidated list of securities holders exercising the right to purchase shares offered to existing shareholders provided by VSDC (for deposited shareholders) and monitored by the Company (for non-deposited shareholders).

(\*\*\*\*\*) Note: The ownership ratio is calculated based on the number of voting shares (30,607,558 shares).

## VI. Attachments

1. Confirmation letter issued by the bank where the escrow account is opened regarding the proceeds collected from the offering, dated January 8, 2026;
2. Board Resolution No. 15/NQ-AGP.HĐQT dated November 13, 2025 of Agimexpharm Pharmaceutical Joint Stock Company regarding the record date for exercising the right to purchase shares from the additional public offering of shares to existing shareholders;
3. Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the exercise of subscription rights and the plan for handling unsubscribed shares in the additional public offering of shares to existing shareholders;
4. Board Resolution No. 02/NQ-AGP.HĐQT dated January 9, 2026 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the additional public offering of shares to existing shareholders;
5. Notice No. 01/TB-AGP dated January 9, 2026 of Agimexpharm Pharmaceutical Joint Stock Company regarding the change in the number of voting shares;
6. Official Letter No. 01/CV-AGP dated January 9, 2026 of Agimexpharm Pharmaceutical Joint Stock Company providing an explanation of the balance stated in the Report on the results of the additional public offering of shares.

An Giang, January 09, 2026

**AGIMEXPHARM PHARMACEUTICAL JSC**

**LEGAL REPRESENTATIVE**

**GENERAL DIRECTOR**



**NGUYEN VAN KHA**



# APPENDIX I: LIST OF INVESTORS ALLOCATED FRACTIONAL SHARES ARISING FROM ROUNDING DOWN

*(Attached to the Report on Results of the public share offering No. 01/BC-AGP dated January 09, 2026)*

No.	Investor/ Related person	ID Card No.	Relationship with the Company/ Internal person/ Major shareholder	Before the offering		In offerings/ issuances within the most recent 12 months		During the offering			After the offering	
				Number of shares	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Number of shares re- allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares	Ownership ratio based on charter capital (30,607,558 shares)
1	Nguyen Thien Tri								344			



**APPENDIX II: LIST OF INVESTORS ALLOCATED UNSUBSCRIBED SHARES  
DUE TO EXISTING SHAREHOLDERS' FAILURE TO REGISTER OR PAY FOR THE SUBSCRIPTION**

(Attached to the Report on Results of the public share offering No. 01/BC-AGP dated January 09, 2026)

No.	Investor/ Related person	ID Card No.	Relationship with the Company/ Internal person/ Major shareholder	Before the offering		In offerings/ issuances within the most recent 12 months		During the offering			After the offering	
				Number of shares	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Number of shares re- allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares	Ownership ratio based on charter capital (30,607,558 shares)
1	Huynh Hoang Ha		Member of the Board of Directors, Deputy General Director						4,859			
	<i>Affiliated person: Le Thi Thu Truc</i>		<i>Wife of Mr. Huynh Hoang Ha</i>						-			
	<i>Affiliated person: Huynh Hoang Sang</i>		<i>Elder brother of Mr. Huynh Hoang Ha</i>						-			
2	Vu Minh Tuan		Deputy General Director						20,000			
3	Tran Nguyen Minh Hien		Chief Accountant						4,000			
4	Quach Thi Bach Huyen		Employee						3,000			



No.	Investor/ Related person	ID Card No.	Relationship with the Company/ Internal person/ Major shareholder	Before the offering		In offerings/ issuances within the most recent 12 months		During the offering			After the offering	
				Number of shares	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Number of shares re- allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares	Ownership ratio based on charter capital (30,607,558 shares)
	<i>Affiliated person: Quach Hai Tho</i>		<i>Husband of Ms. Quach Thi Bach Huyen</i>						-			
5	Nguyen Thi Hong Ngoc		Employee						4,000			
	<i>Affiliated person: Nguyen Hong Phuc</i>		<i>Elder brother of Ms. Nguyen Thi Hong Ngoc</i>						-			
6	Truong Vuong Quoc Vu		Employee						4,000			
	<i>Affiliated person: Truong Vuong Quoc Hoang</i>		<i>Elder brother of Mr. Truong Vuong Quoc Vu</i>						-			
	<i>Affiliated person: Truong Vuong Quoc Toan</i>		<i>Younger sister of Mr. Truong Vuong Quoc Vu</i>						3,000			
7	Nguyen Thi Minh Trang		Employee						3,000			



No.	Investor/ Related person	ID Card No.	Relationship with the Company/ Internal person/ Major shareholder	Before the offering		In offerings/ issuances within the most recent 12 months		During the offering			After the offering	
				Number of shares	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Number of shares re- allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares	Ownership ratio based on charter capital (30,607,558 shares)
	<i>Affiliated person: Huynh Lam Tuan</i>		<i>Husband of Ms. Nguyen Thi Minh Trang</i>						-			
8	Truong Vuong Quoc Toan		Employee						3,000			
	<i>Affiliated person: Truong Vuong Quoc Vu</i>		<i>Elder brother of Ms. Truong Vuong Quoc Toan</i>						4,000			
	<i>Affiliated person: Truong Vuong Quoc Hoang</i>		<i>Elder brother of Ms. Truong Vuong Quoc Toan</i>						-			
9	Le Thi Tuyet		Employee						2,000			
10	Nguyen Xuan Anh Truc		Employee						1,000			
11	Duong Anh Ngoc		Employee						4,000			
	<i>Affiliated person:</i>		<i>Younger brother of</i>						-			



No.	Investor/ Related person	ID Card No.	Relationship with the Company/ Internal person/ Major shareholder	Before the offering		In offerings/ issuances within the most recent 12 months		During the offering			After the offering	
				Number of shares	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares allocated	Number of shares re- allocated	Ownership ratio based on charter capital (26,615,268 shares)	Number of shares	Ownership ratio based on charter capital (30,607,558 shares)
	Duong Anh Tuan		Ms. Duong Anh Ngoc									
12	Luu Nguyen Hien Van		Employee						2,000			
	Affiliated person: Luu Tan Loc		Elder brother of Ms. Luu Nguyen Hien Van						4,000			
13	Nguyen Xuan Thao		Employee						2,375			
	Affiliated person: Le Hong Mai		Mother of Ms. Nguyen Xuan Thao						-			
	Affiliated person: Nguyen Duc Tung		Younger brother of Ms. Nguyen Xuan Thao						-			
14	Luu Tan Loc		Investor						4,000			
	Affiliated person: Luu Nguyen Hien Van		Younger sister of Mr. Luu Tan Loc						2,000			

*Notes:*

- The number of shares re-allocated to investors and their related persons who purchased the unsubscribed shares (pursuant to Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the exercise of subscription rights and the plan for handling unsubscribed shares in the additional public offering of shares to existing shareholders) in this offering complies with the provisions of Article 42 of Decree No. 155/2020/ND-CP dated December 31, 2020 of the Government, detailing the implementation of a number of articles of the Law on Securities.
- The number of shares after the offering includes: [the number of shares held prior to the offering (as of November 27, 2025)], [the number of shares subscribed through the exercise of subscription rights by shareholders], and [the number of shares subsequently allocated in this offering].
- All investors purchasing the unsubscribed shares (pursuant to Board Resolution No. 16/NQ-AGP.HĐQT dated December 31, 2025 of Agimexpharm Pharmaceutical Joint Stock Company approving the results of the exercise of subscription rights and the plan for handling unsubscribed shares in the additional public offering of shares to existing shareholders) are domestic investors.